Sort
21,281 grants matching “influenza”
Immunization Delivery in Obstetrics and Gynecology Settings
$299,987Amanda F Dempsey · University Of Colorado Denver · U01 · FY2011 · IP
BROADLY PROTECTIVE AVIAN INFLUENZA VACCINES FOR POULTRY: IDENTIFICATION OF VIRAL PROTEINS INDUCING CELL-MEDIATED PROTECTION IN CHICKENS
$299,985University Of Maryland, College Park · · FY2025 · National Institute of Food and Agriculture
PA21259, SBIR Phase I, Developing a RIG-I agonist to prevent COVID-19
$299,984Bryan Berube · Hdt Bio Corporation · R43 · FY2022 · IP
Novel Vaccine Immunogens for Pandemic H5 Influenza
$299,983Robert Gerald Whalen · Maxygen, Inc. · R43 · FY2008 · AI
Avian Influenza: Modeling, Analysis and Implications for Control
$299,973Maia N Martcheva · University Of Florida · · FY2012 · MPS
Broad-spectrum, multivalent platform for pan-influenza vaccine
$299,968David William Buchholz · Viva Viral Vaccines, Inc. · R41 · FY2025 · AI
EAGER: DECOMPOSING COVID-19 VIRUS USING THE DUAL ACTION OF MICROWAVES AND PLASMA
$299,963Samir El-Ghazaly · University Of Arkansas · · FY2020 · ENG
Combustion Generated Particulate Pollution Affects Infant Respiratory Health
$299,950Stephania A Cormier · University Of Tennessee Health Sci Ctr · R01 · FY2013 · ES
IMMUNOGENICITY TESTING OF A FULLY SYNTHETIC SUBUNIT VACCINE AGAINST INFLUENZA
$299,940Catherine H Charles · Medivas, Llc · R43 · FY2008 · AI
EPIDEMIOLOGY OF INFLUENZA IN CAMBODIA
$299,937Sirenda Vong · Institut Pasteur Du Cambodge · U01 · FY2007 · IP
Self-Administered Vaccination Electromechanical Device for Influenza
$299,931Kevin Marchitto · Rocky Mountain Biosystems, Inc. · R43 · FY2008 · AI
PA21259, SBIR, Phase I, Improving T cell Responses in Vaccines: Prediction and Validation Using Existing Databases, Immunoinformatics and In Vitro Assays
$299,930Mayara Grizotte-Lake · Epivax, Inc. · R43 · FY2022 · IP
Novel C. Difficile Vaccine Using Nano-vesicle Delivery System
$299,928Christopher Locher · Versatope Therapeutics, Inc. · R43 · FY2020 · AI
DNA Prime / Subunit Boost Multi-Antigen Universal Influenza Vaccine
$299,921Jennifer A Schwartz · Profectus Biosciences, Inc. · R43 · FY2016 · AI
A Novel Broad-spectrum Antiviral Agent
$299,916Joana M Murad · Celdara Medical, Llc · R41 · FY2021 · AI
Applying Association Mining and Group Based Trajectory Analyses to Characterize Spatial Temporal Trends of Community-Onset Antibiotic Resistant Staphylococcus aureus Infections in Children
$299,914Lilly Hsi-Chih Immergluck · Morehouse School Of Medicine · U54 · FY2025 · MD
Study of hemagglutinin membrane fusion domain
$299,905Ad Bax · National Institute Of Diabetes And Digestive And Kidney Diseases · ZIA · FY2011 · DK
mTOR Regulation of Basal Antiviral Immunity in the Elderly
$299,903Joan Mannick · Tornado Therapeutics, Inc. · R01 · FY2023 · AG
A biophysical assay targeting SARS CoV-2 RNA
$299,900Sandra Paige Story · Nubad, Llc · R43 · FY2022 · AI
Sustaining Influenza Surveillance Networks and Response to Seasonal
$299,898Maria Cabello · Direccion Gen De Vigilancia De La Sa · U51 · FY2013 · IP
Low Dose Oral Carbon Monoxide Therapeutic for Virus-Induced Lung Injury
$299,894Edward Gomperts · Hillhurst Biopharmaceuticals, Inc. · R41 · FY2023 · AI
Low Dose Oral Carbon Monoxide Therapeutic for Virus-Induced Lung Injury
$299,894Edward Gomperts · Hillhurst Biopharmaceuticals, Inc. · R41 · FY2022 · AI
Joint Initiative in Vaccine Economics 5
$299,894David W Hutton · University Of Michigan At Ann Arbor · U01 · FY2015 · IP
Agonists of the RIG-I Innate Immune Pathway
$299,892Shawn Patrick Iadonato · Kineta, Inc. · R43 · FY2008 · AI
A Vaccination SOP Toolkit in Diverse Practices Implemented & Tested with RE-AIM
$299,889Richard K Zimmerman · University Of Pittsburgh At Pittsburgh · U01 · FY2012 · IP